A phase II study of everolimus for advanced melanoma patients with mTOR mutations

Category Primary study
JournalJournal of Clinical Oncology
Year 2015
This article has no abstract
Epistemonikos ID: fa80963337a497956bb18d6336d577bd29a152b8
First added on: Feb 07, 2025